.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XL03_AxicabtageneCiloleucel.AxicabtageneCiloleucel .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XL03_AxicabtageneCiloleucel.AxicabtageneCiloleucel| name: | AxicabtageneCiloleucel |
| ATC code: | L01XL03 | route: | intravenous |
| n-compartments | 1 |
Axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy (CAR-T cell therapy), used in the treatment of certain types of relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma. It is approved by regulatory agencies such as the FDA and EMA for clinical use.
Pharmacokinetics in adult patients with relapsed or refractory large B-cell lymphoma treated with a single intravenous infusion; most PK data is based on expansion and persistence of CAR-T cells in circulation rather than traditional small molecule PK models.
Chartier, M, et al., & Shen, R (2024). Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma. Clinical pharmacokinetics 63(9) 1283–1299. DOI:10.1007/s40262-024-01413-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/39240498